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Stem cell factor (SCF), also named mast cell growth factor or Steel
factor, is the ligand for the tyrosine kinase receptor that is encoded
by the c-Kit proto-oncogene (Zsebo et al, 1990). In c-Kit-
expressing cells like mast cells and melanocytes, SCF plays a key
role in several developmental and functional processes (Grabbe
et al, 1994). Thus, SCF regulates induction of proliferation, differ-
entiation, survival, integrin expression, migration and melanin
pigmentation in melanoblasts (Miura et al, 1992; Lahav et al,
1994; Scott et al, 1994; Luo et al, 1995; Sviderskaya et al, 1995;
Costa et al, 1996; Guo et al, 1997). Furthermore, SCF induces an
increase of melanocyte numbers after subcutaneous injections
(Grichnik et al, 1995; Costa et al, 1996).
SCF is produced by diverse cell types, including fibroblasts,
keratinocytes and endothelial cells (Grabbe et al, 1994). A natu-
rally occurring, soluble SCF form is released by extracellular
proteolytic cleavage of the SCF protein at amino acid 165 near its
transmembrane domain (SCF-1 or sSCF), possibly via the action
of mast cell-specific chymase (Longley et al, 1997). An alterna-
tively spliced mRNA lacking the codon for exon 6 and in turn
encoding for amino acids that include the proteolytic cleavage site,
induces translation of a functional SCF variant that tends to remain
membrane-bound (SCF-2 or mSCF) (Flanagan et al, 1991; Huang
et al 1992; Grabbe et al, 1994; Majumdar et al, 1994). The two
SCF forms play distinct roles in the dispersal of normal
melanocyte precursors, with SCF-1 being involved in the migra-
tion of the cells from the neural crest, whereas SCF-2 affects
melanocyte survival and differentiation in the skin (Wehrle Haller
et al, 1995). Using immunohistochemistry, Takahashi et al
detected that few normal cutaneous melanocytes express SCF
itself (Takahashi et al, 1995), and an SCF-dependent autocrine
regulation of early melanogenesis has been discussed by Guo et al
(1997). Expression of the splice variants has so far not been
described in melanocytes, but both molecules have been detected
in whole bone marrow, bone marrow stroma, peripheral blood
neutrophils, human mast cells and HL-60 cell lines (Ramenghi et
al, 1994; Welker et al, 1999). SCF as well as c-Kit have so far been
demonstrated in various solid tumours and tumour cell lines
(Turner et al, 1992; Cohen et al, 1994; Grabbe et al, 1994; Inoue
et al, 1994), including malignant melanoma (Turner et al, 1992;
Luo et al, 1995; Papadimitriou et al, 1995; Takahashi et al, 1995).
In these studies, different cell types were found to vary widely in
their ability to express either molecule. A potential prognostic
significance of ligand or receptor have so far, however, only been
explored for c-Kit. Thus, Natali et al (1992) reported that the
progression of human cutaneous melanoma is associated with a
loss of c-Kit expression. Furthermore, Huang et al (1996)
observed that SCF induces increased retardation of melanoma
growth, fewer lung metastases and increased apoptosis of
melanoma cells overexpressing c-Kit. SCF–c-Kit interaction has
also been shown to regulate melanocyte integrin expression (Scott
et al, 1994), and integrins have recently been implicated in the
process of melanoma metastasis (Schadendorf et al, 1993a, 1996).
Expression of SCF-1 (sSCF) or SCF-2 (mSCF) by melanoma cells
might thus also have prognostic implications.
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Summary Stem cell factor (SCF), the ligand for c-Kit, is known to regulate developmental and functional processes of haematopoietic stem
cells, mast cells and melanocytes. Two different splice variants form predominantly soluble (sSCF or SCF-1) and in addition some membrane-
bound SCF (mSCF or SCF-2). In order to explore the prognostic significance of these molecules in melanoma, total SCF, SCF splice variants
and c-Kit expression were studied in normal skin melanocytes and in 11 different melanoma cell lines, using reverse transcription polymerase
chain reaction, immunocytochemistry and enzyme-linked immunosorbent assay. Nine of the 11 melanoma cell lines expressed SCF-1 mRNA,
only two of them SCF-2, and these two also SCF-1. Coexpression of both SCF-1 and c-Kit was noted in five cell lines, and only one cell line
as well as normal melanocytes expressed both SCF-1 and SCF-2 as well as c-Kit. Corresponding results were obtained on
immunocytochemical staining. Of three exemplary melanoma cell lines studied, two expressing SCF mRNA also released SCF
spontaneously and on stimulation, whereas the line lacking SCF and c-kit mRNA (SK-Mel-23) failed to do so. These data demonstrate thus
that melanoma cell lines, particularly those known to metastasize in vivo, lose the ability to express SCF-2 mRNA, suggesting that this
molecule may serve, next to c-Kit, as a prognostic marker for malignant melanoma. © 2000 Cancer Research Campaign
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DOI: 10.1054/ bjoc.1999.1076, available online at http://www.idealibrary.com on We have therefore investigated here the expression of c-Kit and
both SCF-1 and SCF-2 in normal cutaneous melanocytes and in 11
different melanoma cell lines derived from primary melanomas
or metastases at the protein and m-RNA level. Since the majority
of the cell lines examined had previously been characterized
regarding their metastatic potential in nude mice (Schadendorf
et al, 1996), and since SCF-2-positive cell lines failed to metasta-
size in this model, SCF-2 expression may serve as a prognostic
factor in melanoma.
MATERIALS AND METHODS
Cells
Cutaneous melanocytes, fibroblasts and keratinocytes were
isolated from human foreskin specimens and cultured in special
media allowing only growth of the respective cell type, as previ-
ously described (Grabbe et al, 1996). Melanocytes were kept in a
special melanocyte growth medium (MGM-3, Bio-Whittaker,
Walkersville, MD, USA) and made up 100% of cells after 1 week
of culture, as determined with a melanocyte-specific antigen
(TA99), (Dippel et al, 1995). Human melanoma cell lines WM 98-
1 and WM 1341 were derived from primary melanomas (Herlyn
et al, 1985, 1990; Lu et al, 1993) and were kindly provided by Dr
M Herlyn (Wistar Institute, Philadelphia, PA, USA). MV3 human
melanoma cells were established from a metastatic melanoma
lymph node (van Muijen et al, 1991) and were kindly provided by
Dr GN van Muijen (Nijmegen, The Netherlands). Several human
melanoma cell lines were newly established and included two
from cutaneous metastases (M7 and M13) (Dr U Morowietz, Kiel,
Germany) (Schadendorf et al, 1996), one from a metastatic pleural
effusion (UKRV-Mel-2), and one from a liver metastasis of a
patient with an ocular melanoma (UKRV-Mel-4) (Artuc et al,
1995). SK-Mel-29 and MeWo, two human melanoma cell lines
derived from metastatic lesions of patients with malignant
melanoma, were kindly provided by the Memorial Sloan Kettering
Cancer Center, New York, USA (a gift from Dr LJ Old). All cell
lines were cultured in RPMI-1640 medium supplemented with
10% fetal calf serum, as described previously (Schadendorf et al,
1993b).
Reverse transcription-polymerase chain reaction
Cells were lysed and total RNA prepared using the RNeasy-total-
RNA-kit (Quiagen, Hilden, FRG). cDNA was synthesized by
reverse transcription of 5 mg total RNA, using a cDNA synthesis
kit (InVitrogen, Stade, USA). The following sets of oligonucleo-
tide primers were used to amplify cDNA: GAPDH: 5¢-GAT GAC
ATC AAG AAG GTG GTG and 5¢-GCT GTA GCC AAA TTC
GTT GTC (197 bp) (Tokunaga et al, 1987), for c-Kit: 5¢-CGT
TGA CTA TCA GTT CAG CGA G and 5¢-CTA GGA ATG TGT
AAG TGC CTC (369 bp) (Ratajczak et al, 1992), SCFtotal –
primer-set I: 5¢-GGG CTG GAT CGC AGC GC and 5¢-CTC CAC
AAG GTC ATC CAC SCF1+2 – primer set II: 5¢-CTT CAA CAT
TAA GTC CCT GAG and GTG TAG GCT GGA GTC TCC
(Longley et al, 1993). SCF-2 – primer set III: 5¢-CTT GTG GAG
TGC GTC AAA GA and 5¢-TTG GCC TTC CCT TTC TCA GG.
The expected fragment length was 276 bp for SCF primer-set I,
359 or 275 bp for SCF primer set II, dependent on the presence
(SCF-1) or absence (SCF-2) of exon 6, and 199 bp for primer set
III. The primer set III is specific for SCF-2 since it crosses the
exon 5/7 boundary (10 bp of exon 5 and 10 bp of exon 7).
Amplification was performed using Taq polymerase (Gibco) over
24–35 (40 cycles using primer set III) cycles with an automated
thermal cycler (Perkin-Elmer, Weiterstadt, Germany). Each cycle
consisted of the following steps: denaturation at 94°C, annealing
at 58°C and extension at 72°C for 1 min each. For semiquantita-
tive reverse transcription polymerase chain reaction (RT-PCR),
cDNA from the different cell types was adjusted to equal quanti-
ties by serial dilutions, controlled by PCR amplification using
primers of the housekeeping gene glyceraldehyde 3-phosphate
dehydrogenase (GAPDH), as previously described (Grabbe et al,
1996). Linearity of the signal for GAPDH was determined
between 24 and 27 cycles, and for the other markers between 30
and 35 cycles. PCR products were analysed by agarose gel elec-
trophoresis using standard techniques, and staining intensity was
quantitatively assessed by densitometric analysis with a video
scanner (Biometra, Göttingen, Germany).
Immunocytochemical staining
Immunocytochemistry was performed and evaluated on cytocen-
trifuge preparations of cells stained with the APAAP technique, as
previously described (Hamann et al, 1994). Three different anti-
bodies against SCF were used, a monoclonal antibody against SCF
purchased from Genzyme (Cambridge, MA, USA), a mouse
monoclonal antibody (HKL-12), and a rabbit polyclonal anti-
body (7278) (Hamann et al, 1995), both kindly donated by
M Brockhaus, Basel, Switzerland. IgG1 was used as control and
purchased from Dianova (Hamburg, Germany).
Quantification of SCF protein
SCF in supernatants of cells seeded at 1 ´ 106 ml–1 and cultured for
24 h in medium alone or stimulated with calcium ionophore
A23187 (0.1 mM, Sigma, Deisenhofen, Germany) was measured
using a commercial ELISA kit purchased from R&D Systems
(Minneapolis, MN, USA). In addition, cells were incubated with
10 ng ml–1 mouse-SCF (no cross reactivity in the ELISA kit), to
displace SCF produced by melanocytes and potentially bound to
its own SCF receptor on these cells.
RESULTS
SCF-specific m-RNA expression in melanocytes and
melanoma cell lines
Evaluation of mRNA was done semiquantitatively by RT-PCR,
using primer sets specific for c-Kit, SCFtotal, and the splice variants
SCF-1/SCF-2, or SCF-2 alone in comparison to GAPDH (Figure
1). The densitometric analysis of these data is shown in Table 1.
Normal melanocytes were used as positive control (Figure 1) and
yielded bands with the c-Kit and all SCF primers. Nine of the 11
melanoma lines also gave a positive signal with SCF primer set I
which detects both splice variants of SCF with one signal (SCFtotal)
(Figure 1). With SCF primer set II which differentiates between
the two splice variants, only two of these SCF-positive cell lines
expressed SCF-2 (UKRV-Mel-4, WM 1341).
These results were confirmed by using a third primer set which
is specific for the amplification of the SCF-2 splice variant with
higher sensitivity. On RT-PCR analysis (Figure 1), a signal is
evident in normal melanocytes and in the same two cell lines
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signal is detectable in MeWo and SK-Mel-29. In only five of the
SCF-positive cell lines, a signal was also found for c-Kit-specific
m-RNA. Two cell lines failed to react with any of the primers
studied, and four c-Kit-negative cell lines still produced SCFtotal
(Table 1).
In a previous investigation (Schadendorf et al, 1996), the
metastatic potential of eight of the 11 melanoma cell lines studied
here was examined in vivo in a nude mouse model (Table 1).
Interestingly, all five melanoma cell lines which were able to
induce metastases in nude mice entirely lacked c-Kit or expressed
it at a very low level. On the other hand, of the three tumours
which had failed to induce metastases in vivo, two (MeWo and
UKRV-Mel-4) were strongly positive for c-Kit, and the other two
(UKRV-Mel-4 and WM1341) were the only cell lines expressing
SCF-2. In the remaining cell lines, the signal intensity for SCF-1
failed to correlate with their ability to induce metastases.
Comparison of melanocyte SCF-expression with other
SCF-producing cells
Besides melanocytes, several other cell types in the immediate
vicinity of melanocytes and melanomas in the skin have also been
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Figure 1 Expression of m-RNA (semiquantitative RT-PCR) for GAPDH,
c-Kit, SCFtotal (using primer set I) and SCF-1 and -2 (using primer set II to
differentiate between full-length and spliced forms of SCF), and SCF-2 (using
primer set III) (representative results from one of three experiments):
1: negative control (without c-DNA), 2: MeWo, 3: WM-98-1, 4: UKRV-Mel-4,
5: M13, 6: M7, 7: WM1341, 8: UKRV-Mel-2, 9: SK-Mel-29, 10: SK-Mel-23,
11: SK-Mel-37, 12: MV3, 13: normal human skin melanocytes (positive
control)
Table 1 Densitometric data (signal intensity) of RT-PCR analysis (Figure 1)
regarding c-kit and SCF mRNA expression in melanoma cell lines. All
c-DNAs were normalized to the same level, using GAPDH as house-keeping
gene
Cell lines c-kit SCFtotal SCF-1 SCF-2 Formation of 
metastases
in nude micea
MeWo 450 300 180 0 –
WM 98-1 0 80 20 0 +
UKRV-Mel-4 380 410 230 100 –
M13 30 10 30 0 +
M7 0 300 100 0 +
WM 1341 0 390 150 30 –
UKRV-Mel-2 0 0 0 0 +
SK-Mel-29 290 60 10 0 ND
SK-Mel-23 0 0 0 0 ND
SK-Mel-37 300 50 0 0 ND
MV3 0 120 160 0 +
a Cell lines shown to induce metastases (+) or failing to do so (–) in nude
mice (Schadendorf et al, 1996). ND – not done.
GAPDH
SCF
1 2 3 4 5
Figure 2 Semiquantitative RT-PCR for GAPDH and SCF (primer set I)
(representative results from one of three experiments): 1: negative. control
(without c-DNA), 2: skin melanocytes, 3: MeWo, 4: skin fibroblasts, 5: skin
keratinocytes
Table 2 Release of SCF from unstimulated and stimulated melanoma cell
lines
Melanoma cell Incubation with Incubation with Release of SCF
line Ca-ionophorea mouse SCFa (pg/106 cells)
MEWO – – 80 ± 10
– + 75 ± 15
+ – 85 ± 10
+ + 115 ± 20
UKRV-Mel-4 – – 55 ± 5
– + 55 ± 10
+ – 70 ± 10
+ + 60 ± 10
SK-Mel-23 – – 0
–+ 0
+–0
++0
(Means ± s.d. of n = 3 separate experiments) afor 24 h.demonstrated to produce SCF. In order to assess the relative
contribution of these cells compared to melanocytes regarding
SCF expression, we studied the mRNA expression of SCFtotal in
fibroblasts, keratinocytes, melanocytes and MeWo cells. This cell
line was chosen because it expresses medium quantities of SCF,
compared to the other melanoma cell lines. Figure 2 shows repre-
sentative data of the semiquantitative RT-PCR for SCF expressed
by the different cell types. On densitometric analysis, signal
intensities were clearly lower for melanocytes and MeWo cells,
compared to the other cell types, but they still ranged within the
same order of magnitude (melanocytes: 120; MeWo: 85; fibro-
blasts: 310; keratinocytes 400).
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Figure 3 Immunoreactivity of MeWo cells (A), WM 98-1 (B), UKRV-Mel-4 (C), WM 1341 (D), UKRV-Mel-2 (E), MV3 (F) and normal skin melanocytes (G) to a
monoclonal antibody against SCF HKL-12 (APAAP technique, magnification: A–F: ´ 400; G: ´ 1000)Production and release of SCF protein in melanocytes
Analysis of the intensity of staining for SCF on immunocytochem-
istry (Figure 3) correlated well with the data obtained on semi-
quantitative m-RNA analysis and held for all three different SCF
antibodies tested. Interestingly, APAAP staining with the HKL-12
antibody exhibited cytoplasmatic as well as cell membrane SCF
expression in the cell lines which had yielded an m-RNA signal for
SCF-2 (UKRV-Mel-4, WM1341).
In order to examine whether these cells are also able to release
SCF, we cultured three different cell lines (two positive and one
negative for SCF on RT-PCR) for 24 h in serum-free culture
medium alone or with Ca-ionophore A23187 added (Table 2). SCF
protein was measurable in supernatants of the unstimulated and
stimulated SCF-mRNA-positive cell lines (Table 1 and Figure 1)
at approximately the same levels, whereas the SCF-mRNA-nega-
tive melanoma line released no measurable SCF under either
condition. Since the first two melanoma cell lines studied also
express the receptor for SCF and since part of the SCF secreted
might be immediately bound to the receptor after release, mouse
SCF was added to the cultures in order to prevent any binding of
secreted SCF to its receptor (there is no cross-reactivity with
mouse SCF on ELISA). As can be seen in Table 2, a substantial
increase of measurable SCF was detected only in supernatants of
ionophore-stimulated MeWo cells.
DISCUSSION
In the present study, melanocytes are shown for the first time to
express both splice variants of SCF, namely SCF-1 and SCF-2.
Since they also express c-Kit, cutaneous melanocytes are like mast
cells potentially subject to autocrine regulation, in contrast to
neutrophils and HL-60 cells which have been reported to express
both splice variants of SCF, but not c-Kit (Ramenghi et al, 1994;
Welker et al, 1999).
In contrast to melanocytes, the expression of these molecules is
partially and variably lost in melanoma cell lines, particularly with
regard to SCF-2. If present, SCF expression is, however, compa-
rable to that in melanocytes and lower compared to keratinocytes
and fibroblasts. These latter can thus potentially exert control over
normal growth and differentiation of melanocytes in the basal
layer of the epidermis.
So far, differentiation between the SCF-splice variants in
melanoma lines has been reported only for the HT144 cells which
also express c-Kit (Turner et al, 1992). SCF mRNA has been
described in all five different melanoma lines studied by another
group, although the splice variants were not distinguished
(Papadimitriou et al, 1995). Concurrent expression of c-Kit and
SCF-mRNA was found on only three of these five cell lines, and c-
Kit protein even in only one of them, namely in MeWo cells which
were also included in the present study. Another group detected
SCF protein in only one of five melanoma cell lines, none of which
expressed c-Kit, whereas benign melanocytic naevi expressed both
molecules (Takahashi et al, 1995). In the present study, c-Kit
mRNA was identified in five of the 11 cell lines, in agreement with
a previous report from our group regarding c-Kit protein expres-
sion in melanoma cell lines (Worm et al, 1993). Interestingly,
immunohistochemical studies demonstrated that melanocytic
naevus cells express c-Kit only in the epidermal and not in the
dermal compartment (Grabbe et al, 1994; Takahashi et al, 1995).
Dermal melanocytic naevus cells also lack pigmentation,
suggesting that they are no longer subject to SCF-dependent
melanogenesis. Taken together, these observations suggest that
melanocytic cells lose the ability to express SCF and c-Kit,
possibly in dependence of their life cycle and/or in response to
their microenvironment.
There are a number of indications that SCF control over the cell
might regulate tumour development and spread. Thus, although
the factor has no major effects on growth of different cell lines
(Papadimitriou et al, 1995), it has been reported that an enforced
overexpression of c-Kit renders melanoma cells susceptible to
stem cell factor-induced apoptosis and inhibits the tumorigenic
and metastatic potential of the cells (Huang et al, 1996). The
degree of SCF expression could, however, not be correlated with
metastatic potential until now. The present data, showing that the
splice variant which encodes for the mainly membrane-bound
SCF-2 and not the total SCF-specific m-RNA is important, shed
new light on this question. Thus, only those melanoma cell lines
which express neither c-Kit m-RNA (cell line M13 minimal
amounts) nor SCF-2 m-RNA have in the past been shown to
induce metastases in the nude mice model (Table 1).
Previous studies have shown that membrane bound forms of
various growth factors, like SCF, are able to interact with their
respective receptor expressed by a neighbouring target cell
(juxtacrine interaction) (Bosenberg et al, 1993). This membrane-
bound factor which is biologically as active as a freely diffusible
factor, may similarly mediate specific cell-to-cell contacts,
enhancing differentiation and survival of neighbouring
melanocytes. Possibly, c-Kit and membrane-bound SCF-2 is also
of importance on interaction of melanocytic cells and mast cells,
the only other skin cells expressing c-Kit-like melanocytes. Mast
cells are located primarily in the upper dermis, only rarely in the
epidermis, and they have been shown to increase in number and
infiltrate dermal melanomas (Schadendorf et al, 1995). The poten-
tial functional significance of mast cells in melanomas is, however,
as yet unclear, as is their prognostic significance, although direct
interaction with melanoma cells via SCF-2/c-Kit is well possible.
Mast cell infiltration may on the other hand be induced, next to
anaphylatoxins, by chemotactically active SCF-1 released from
melanoma cells as well as surrounding endothelial cells, fibro-
blasts and keratinocytes (Grabbe et al, 1994; Hartmann et al, 1998).
Taken together, soluble and membrane-bound SCF may func-
tion in an autocrine and paracrine fashion, modulating melanin
synthesis and apoptosis of melanocytic cells and potentially also
their tumorigenic potential. The relative prognostic significance of
the splice variants of SCF and c-Kit in melanoma, and particularly
of SCF-2 which is strikingly rare in melanoma cell lines, as
observed here, will have to be further confirmed in studies of
primary and metastatic melanoma, placing its expression in rela-
tionship to patients’ prognosis.
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